COVID-19 Update: Biogen is committed to continuing to provide support for our patients during these unprecedented times. Biogen Support Services is here to help your patients get started on treatment and provide additional support throughout their time on a Biogen therapy. For information about Biogen initiatives in response to the COVID-19 outbreak, please visit Biogen COVID-19 Information Center.

Close
Biogen

Understanding Biogen
Biosimilar Support Services

Help Support Your Patients With Financial and Insurance Assistance

Biogen Biosimilar Support Services can:

  • Investigate patient insurance benefits to help understand current coverage
  • Communicate prior authorization requirements for treatment
  • Provide support in the event of denied insurance claims
  • Educate patients on their eligibility for financial support options
  • Supply resources for patients to explore other insurance options
  • Answer other questions you or your practice may have about BYOOVIZ

Individuals on nongovernment insurance may be eligible for the Drug Copay Program, regardless of income. The patient’s insurance will be billed first and must pay before copay assistance will be applicable. Restrictions may apply.*

  • *
  • There may be an annual cap on the amount of assistance that patients can receive over a one-year period. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, VA/DoD, or any other federal plans are not eligible to enroll. Clinical and other restrictions may apply. Patients are eligible to enroll in the Biogen Copay Program for as long as it is offered and they are treated with BYOOVIZ. Please call Biogen Biosimilar Support Services at 1-877-422-8360 1-877-422-8360 for further details.

In addition to the criteria to be met for the Drug Copay Program, patients prescribed BYOOVIZ for an approved indication may be eligible for the Administration Copay Program if they meet the following requirements:

  • Not a resident of Massachusetts, Minnesota, or Rhode Island
  • The healthcare provider submits a request for treatment using an approved procedure code for drug administration. Only codes approved by Biogen shall be eligible under the program
  • Other restrictions apply

Please note that the Drug Copay Program and Administration Copay Program are different programs with unique eligibility for each. Patients must enroll separately as needed.

  • There may be an annual cap on the amount of assistance that patients can receive over a one-year period. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, VA/DoD, or any other federal plans are not eligible to enroll. Clinical and other restrictions may apply. Patients are eligible to enroll in the Biogen Copay Program for as long as it is offered and they are treated with BYOOVIZ. Please call Biogen Biosimilar Support Services at 1-877-422-8360 for further details.

If it is determined that a patient is not eligible for the Biogen Copay Program, Biogen Biosimilar Support Services may provide contact information for charitable organizations that may provide third-party assistance.

Our Free Drug Program can temporarily provide Biogen products at no cost for individuals who meet certain financial eligibility criteria such as residency requirements, therapy status, income level, and insurance coverage.

The Free Drug Program covers the cost of the drug only. It is not responsible for costs associated with administration of therapy, such as office visits, administration costs, or other professional services.

To learn more information or to enroll your patient in Biogen Biosimilar Support Services, please visit BiogenBiosimilarSupportServices.com

You may also enroll patients by downloading the enrollment form and faxing it to
1-240-696-8830

For more information about these services, contact Biogen Biosimilar Support Services at 1-877-422-8360, Monday through Friday, 8:30 am – 8:00 pm ET

Indications and Important
Safety Information

INDICATIONS

BYOOVIZ™ (ranibizumab-nuna), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Myopic Choroidal Neovascularization (mCNV)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • BYOOVIZ is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in BYOOVIZ
  • Hypersensitivity reactions may manifest as severe intraocular inflammation

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering BYOOVIZ. In addition, patients should be monitored following the injection to permit early treatment should an infection occur

Increases in Intraocular Pressure

  • Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with BYOOVIZ and manage appropriately

Thromboembolic Events

  • Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. Arterial thromboembolic events are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause)
    • Neovascular (Wet) Age-Related Macular Degeneration
    • The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3
      In a pooled analysis of 2-year controlled studies [AMD-1, AMD-2, and a study of ranibizumab used adjunctively with verteporfin photodynamic therapy (PDT)], the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg of ranibizumab compared to 1.1% (5 of 435) in patients in the control arms [odds ratio 2.2 (95% confidence interval (0.8-7.1)]
    • Macular Edema Following Retinal Vein Occlusion
    • The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the ranibizumab and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of ranibizumab-treated patients compared to 0.4% (1 of 260) in the control arms

ADVERSE REACTIONS

  • Serious adverse reactions related to the injection procedure have occurred in < 0.1% of intravitreal injections, including endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract
  • The most common adverse reactions (reported more frequently in ranibizumab-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure
  • As with all therapeutic proteins, there is potential for immunogenicity. The clinical significance of immunoreactivity to ranibizumab products is unclear at this time

Please see full Prescribing Information.

INDICATIONS

BYOOVIZ™ (ranibizumab-nuna), a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Myopic Choroidal Neovascularization (mCNV)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

  • BYOOVIZ is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab products or any of the excipients in BYOOVIZ
  • Hypersensitivity reactions may manifest as severe intraocular inflammation

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

  • Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering BYOOVIZ. In addition, patients should be monitored following the injection to permit early treatment should an infection occur

Increases in Intraocular Pressure

  • Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with BYOOVIZ and manage appropriately

Thromboembolic Events

  • Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. Arterial thromboembolic events are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause)
    • Neovascular (Wet) Age-Related Macular Degeneration
    • The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms. In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. In Study AMD-4, the ATE rates observed in the 0.5 mg arms during the first and second year were similar to rates observed in Studies AMD-1, AMD-2, and AMD-3
      In a pooled analysis of 2-year controlled studies [AMD-1, AMD-2, and a study of ranibizumab used adjunctively with verteporfin photodynamic therapy (PDT)], the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg of ranibizumab compared to 1.1% (5 of 435) in patients in the control arms [odds ratio 2.2 (95% confidence interval (0.8-7.1)]
    • Macular Edema Following Retinal Vein Occlusion
    • The ATE rate in the two controlled RVO studies during the first 6 months was 0.8% in both the ranibizumab and control arms of the studies (4 of 525 in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab and 2 of 260 in the control arms). The stroke rate was 0.2% (1 of 525) in the combined group of ranibizumab-treated patients compared to 0.4% (1 of 260) in the control arms

ADVERSE REACTIONS

  • Serious adverse reactions related to the injection procedure have occurred in < 0.1% of intravitreal injections, including endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract
  • The most common adverse reactions (reported more frequently in ranibizumab-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure
  • As with all therapeutic proteins, there is potential for immunogenicity. The clinical significance of immunoreactivity to ranibizumab products is unclear at this time

Please see full Prescribing Information.